Abstract:AIM: To evaluate the early treatment response to chemotherapy in patients with lung cancer using dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI). MATERIALS AND METHODS: Twenty-two patients with lung cancer underwent DCE-MRI before chemotherapy and 1 week after the start of the first course of chemotherapy. Pharmacokinetic parameters (Ktrans, Kep, and Ve) derived from DCE MRI were generated using the post-processing platform. These parameters and corresponding changes were compared between responders and non-responders after treatment using Student's t or ManneWhitney Utests. Diagnostic efficiency of kinetic parameters in differentiating responders from nonresponders after 1 week of chemotherapy was also investigated. RESULTS: Thirteen responders after 1 week of chemotherapy had a significant decrease in Ktrans and Ve compared with the pretreatment value (p< 0.05), and had no significant changes in Kep (p> 0.05). Nine non-responders had no significant changes in Ktrans, Kep, and Ve compared with the pretreatment value (p> 0.05). Changes in Ktrans (Delta Ktrans) were significantly larger in responders than that in non-responders (p< 0.05). Changes in Ve and Kep (Delta Ve and Delta Kep) were without statistical significance after treatment between responders and nonresponders (p> 0.05). The cut-off value of Delta Ktrans in best predicting tumour's chemotherapeutic response was 0.032/min and the corresponding AUC (area under the curve), sensitivity, specificity, and accuracy were 0.821, 84.62%, 77.78%, and 81.82%, respectively. CONCLUSION: DCE MRI may be useful for evaluating the early response to chemotherapy in patients with lung cancer, but larger, more definitive studies are needed. (C) 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Early Assessment of Response to Chemotherapy in Lung Cancer Using Dynamic Contrast-Enhanced MRI: a Proof-of-concept Study